Progress to Date in Advancing Stratified Medicine in Psoriasis.
Antibodies, Monoclonal, Humanized
Biological Factors
/ pharmacology
Biomarkers
/ analysis
Chronic Disease
/ drug therapy
Clinical Trials as Topic
Dermatologic Agents
/ pharmacology
Genome-Wide Association Study
Humans
Precision Medicine
/ methods
Psoriasis
/ diagnosis
Severity of Illness Index
Th17 Cells
/ drug effects
Treatment Outcome
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
2
7
2020
medline:
25
5
2021
entrez:
2
7
2020
Statut:
ppublish
Résumé
Stratified medicine is the tailoring of treatment to the individual characteristics of each patient. This is a challenging task in the context of psoriasis, a complex disease with a variety of phenotypic presentations and a comorbidity burden that extends beyond cutaneous manifestations. In recent years, considerable progress has been made in understanding the immunology of psoriasis, and this has informed the development of increasingly precise and efficacious therapies. However, not all patients respond to biologic therapy, and access is limited to patients with moderate to severe disease. However, subpopulations of patients are emerging with distinct patterns of response to therapy, largely determined by clinical and pharmacogenomic factors. Despite progress to date, the natural history of psoriasis remains poorly understood. It is likely that disease onset, progression, development of comorbidities and response to therapy are due to a combination of genetic, inflammatory and environmental factors. We envision that a greater understanding of the natural history of psoriasis will be a key factor in progressing a stratified medicine approach to patient care, as will earlier intervention in the course of the disease.
Identifiants
pubmed: 32607944
doi: 10.1007/s40257-020-00533-z
pii: 10.1007/s40257-020-00533-z
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biological Factors
0
Biomarkers
0
Dermatologic Agents
0
guselkumab
089658A12D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
619-626Références
Radtke MA, Langenbruch A, Jacobi A, Schaarschmidt ML, Augustin M. Patient benefits in the treatment of psoriasis: long-term outcomes in German routine care 2007–2014. J Eur Acad Dermatol Venereol. 2016;30:1829–33.
pubmed: 27440750
Kurd S, Troxel A, Crits-Christoph P, Gelfand J. The risk of depression, anxiety and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891–5.
pubmed: 20713823
pmcid: 2928071
Parisi R, Rutter MK, Lunt M, Young HS, Symmons DPM, Griffiths CEM, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol. 2015;135:2189–97.
pubmed: 25742120
Basko-Plluska J, Petronic-Rosic V. Psoriasis: epidemiology, natural history, and differential diagnosis. Psoriasis Targets Ther. 2012;2:67–766.
Cole M, Jones C, Todd I. A new anti-estrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25:270–5.
pubmed: 5115829
pmcid: 2008453
Ran D, Cai M, Zhang X. Genetics of psoriasis: a basis for precision medicine. Precis Clin Med. 2019;2:120–30.
Dand N, Satveer K, Capon F, Smith CH, Simpson MA, Barker JN. Psoriasis and Genetics. Acta Dermato Venereol. 2020;100:54–64.
Trembath R, Clough R, Rosbotham J, Jone A, Camp R, Frodsham A, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6:813–20.
pubmed: 9158158
Li K, Huang C, Randazzo B, Li S, Szapary P, Curran M, et al. HLA-C*06:02 allele and response to IL-12/23 inhibition: results from the ustekinumab phase 3 psoriasis program. J Invest Dermatol. 2016;136:2364–71.
pubmed: 27476722
van Vugt L, van den Reek J, Coenen M, de Jong E. A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis. Br J Dermatol. 2018;178:86–94.
pubmed: 28646581
Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143:2120–30.
pubmed: 30578879
Talamonti M, Galluzzo M, Zangrilli A, Papoutsaki M, Egan C, Bavetta M, et al. HLA-C*06:02 does not predispose to clinical response following long-term adalimumab treatment in psoriatic patients: a retrospective cohort study. Mol Dagnosis Ther. 2017;21:295–301.
Carraro L, Malara G, Bartezaghi M, Flori ML, Costanzo A, Bianchi L, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018;179:1072–80.
pubmed: 29704432
Bachelez H. Pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020;100:87–92.
Robinson A, Van Voorhees A, Hsu S, Korman N, Lebwohl M, Bebo BJ, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:279–88.
pubmed: 22609220
Bachelez H, Choon S, Marrakchi S, Burden A, Tsai T, Morita A, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. New Engl J Med. 2019;7:981–3.
World Health Organisation (WHO) Global Report on Psoriasis. [Internet]. 2016; 48. www.who.int/about/licensing/%0A(www.who.int/about/licensing/%0Acopyright_form/en/index.html)%00 . Accessed 5 Mar 2020.
National Institute for Health and Clinical Excellence Guideline. Psoriasis : assessment and management. Clinical Guideline. Published 24 October 2012. Available at nice.org.uk/guidance/cg153. Accessed 5 Mar 2020
Okada Y, Han B, Tsoi L, Stuart P, Ellinghaus E, Tejasvi T, et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet. 2014;95:162–72.
pubmed: 25087609
pmcid: 4129407
Bowes J, Ashcroft J, Dand N, Jalali-Najafabadi F, Bellou E, Ho P, et al. Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Ann Rheum Dis. 2017;76:1774–9.
pubmed: 28821532
pmcid: 5629941
Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, Yang J, et al. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nat Commun. 2018;9:1–10.
Lu Y, Chen H, Nikamo P, Low HQ, Helms C, Seielstad M, et al. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol. 2013;133:836–9.
pubmed: 23190900
Koch M, Baurecht H, Ried JS, Rodriguez E, Schlesinger S, Volks N, et al. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol. 2015;135:1283–93.
pubmed: 25599394
pmcid: 4402117
Greb JE, Goldminz A, Eder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:1–17.
Fry L. Psoriasis. Br J Dermatol. 1988;119:445–61.
pubmed: 3056491
Boyman O, Conrad C, Tonel G, Gilliet M, Nestle F. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol. 2007;28:51–7.
pubmed: 17197238
Matos T, Malley J, Lowry E, Hamm D, Kirsch I, Robins H, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones. J Clin Invest. 2017;127:4031–41.
pubmed: 28945199
pmcid: 5663366
Iversen L, Eidsmo L, Austad J, de Rie M, Osmancevic A, Skov L, et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification-rationale and design of the randomized, multicenter STEPIn study. J Eur Acad Dermatol Venereol. 2018;32:1930–9.
pubmed: 29633373
Gallais Sérézal I, Classon C, Cheuk S, Barrientos-Somarribas M, Wadman E, Martini E, et al. Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome. J Invest Dermatol. 2018;138:1754–63.
pubmed: 29510191
Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386:2489–98.
pubmed: 26433318
pmcid: 4920221
Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045–50.
pubmed: 24525911
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–77.
pubmed: 28264816
Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn’s disease: towards disease modification trials. Gut. 2017;66:2179–87.
pubmed: 28874419
Smith C, Jabbar-Lopez J, Yiu Z, Bale T, Burden A, Coates L, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2016;38:42–9.
Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135:2632–40.
pubmed: 26053050
Reich K, Griffiths C, Gordon K, Papp K, Song M, Randazzo B, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82:936–45.
pubmed: 31809827
ClinicalTrials.gov [Internet]. Janssen-Cilag G.m.b.H. Identifier: NCT03818035. A study to evaluate further therapeutic strategies with Guselkumab in participants with moderate-to-severe plaque-type psoriasis (GUIDE). https://clinicaltrials.gov/ct2/show/NCT03818035 . Accessed 6 Mar 2020.
Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72:961–7.
pubmed: 25882886
EU clinical trials register [Internet] EudraCT number 2018-004010-18. Almirall Ldt. An Open Label, Multi-Center, 24 Week, Exploratory Study to Assess the Efficacy and Safety of Skilarence
Menter MA, Griffiths CEM. Psoriasis: the future. Dermatol Clin. 2015;33:161–6.
pubmed: 25412790
Reid C, Mason K, Esse S, McElhone K, Lunt M, Cordingley L, et al. Baseline characteristics of patients registering to British Association of Dermatologists Biologics and Immunomodulators Register stratified by disease duration at the time of registration. Br J Dermatol. 2019;181(Suppl S1):47.
Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible versus eligible for randomized controlled trials. Arch Dermatol. 2012;148:463–70.
pubmed: 22508869
Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 2018;154:581–8.
pubmed: 29590279
pmcid: 5876819
Griffiths CEM, Barnes MR, Burden AD, Nestle FO, Reynolds NJ, Smith CH, et al. Establishing an Academic-Industrial Stratified Medicine Consortium: psoriasis stratification to optimize relevant therapy. J Invest Dermatol. 2015;135:2903–7.
pubmed: 26569580
Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, et al. Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatol. 2019;155:1235–43.
pmcid: 6751771
Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, et al. Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. J Invest Dermatol. 2019;139:115–23.
pubmed: 30130616
pmcid: 6300405
Strober B, Ryan C, van der Kerkhof P, van der Walt J, Kimball A, Barker J, et al. Re-categorisation of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82:117–22.
pubmed: 31425723
Thorneloe R, Griffiths C, Emsley R, Ashcroft D, Cordingley L, Groups, and on behalf of the BADBIR, and PSORT study groups. Intentional and unintentional medication non-adherence in psoriasis: the role of patients’ medication beliefs and habit strength. J Invest Dermatol. 2018;138:785–94.
pubmed: 29183731
pmcid: 5869950
Nelson PA, Kane K, Pearce CJ, Bundy C, Chisholm A, Hilton R, et al. “New to me”: Changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well
pubmed: 28403510
pmcid: 5637913
Chisholm A, Nelson PA, Pearce CJ, Littlewood AJ, Kane K, Henry AL, et al. Motivational interviewing-based training enhances clinicians’ skills and knowledge in psoriasis: findings from the Pso Well
pubmed: 27373236
Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, et al. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): Design, methodology and objectives. Br J Dermatol. 2012;166:545–54.
pubmed: 22356636
Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2018;180:1–8.
Iskandar I, Ashcroft D, Warren R, Lunt M, McElhone K, Smith C, et al. Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017;177:1412–21.
Richer V, Roubille C, Fleming P, Starnino T, McCourt C, McFarlane A, et al. Psoriasis and smoking: a systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity. J Cutan Med Surg. 2016;20:221–7.
pubmed: 26553732
Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose–response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33:1163–78.
pubmed: 29680995
pmcid: 6290660
Brenaut E, Horreau C, Pouplard C, Barnetche T, Paul C, Richard MA, et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatology Venereol. 2013;27(suppl. 3):30–5.
Svanström C, Lonne-Rahm S-B, Nordlind K. Psoriasis and alcohol. N Z Med J. 2019;9:75–9.
Ko S, Chi C, Yeh M, Wang S, Tsai Y, Hsu M. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD011972.pub2 .
doi: 10.1002/14651858.CD011972.pub2
pubmed: 31309536
pmcid: 6629583
Ford A, Siegel M, Bagel J, Cordoro K, Garg A, Gottlieb A, et al. Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: a systematic review. JAMA Dermatol. 2018;154:934–50.
pubmed: 29926091
Majeed-Ariss R, McPhee M, McAteer H, Griffiths C, Young H. The top 10 research priorities for psoriasis in the UK: results of a James Lind Alliance psoriasis Priority Setting Partnership. Br J Dermatol. 2019;181:871–3.
pubmed: 31162641
pmcid: 6973084
Kimball AB, Gieler U, Linder D, Sampogna F, Warren R, Augustin M. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol. 2010;24:989–1004.
pubmed: 20477920
Linder M, Piaserico S, Augustin M, Belloni Fortina A, Cohen AD, Gieler U, et al. Psoriasis—the life course approach. Acta Dermatol Venereol. 2016;96(Suppl 217):102–8.
Ding WY, Beresford MW, Saleem MA, Ramanan AV. Big data and stratified medicine: what does it mean for children? Arch Dis Child. 2019;104:389–94.
pubmed: 30266876
Sagner M, McNeil A, Puska P, Auffray C, Price ND, Hood L, et al. The P4 Health Spectrum—A Predictive Preventive, Personalized and Participatory Continuum for Promoting Healthspan. Prog Cardiovasc Dis. 2017;59:506–21.
pubmed: 27546358